Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Biopharmaceutics & drug disposition

• Publication date

  1997-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/(SICI)1099-081X(199705)18:4<347::AID-BDD23>3.0.CO;2-OPMID 9158882
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical pharmacology of high-dose cisplatin

  2004cited by this paper
• Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial

  2004cited by this paper
• Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.

  1994cited by this paper
• Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812)

  1994cited by this paper
• Phase I and pharmacokinetic study of intraperitoneal ormaplatin.

  1993cited by this paper
• Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.

  1993cited by this paper
• Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin.

  1993cited by this paper
• Role of carrier ligand in platinum resistance of human carcinoma cell lines.

  1993cited by this paper
• New Cisplatin Analogues in Development

  1993cited by this paper
• Rapid reduction of tetrachloro(D,L-trans)1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in RPMI 1640 tissue culture medium.

  1989cited by this paper
• In vivo biochemical indices of nephrotoxicity of platinum analogs tetraplatin, CHIP, and cisplatin in the Fischer 344 rat.

  1988cited by this paper
• Comparative toxicity and renal distribution of the platinum analogs tetraplatin, CHIP, and cisplatin at equimolar doses in the Fischer 344 rat.

  1988cited by this paper
• Reaction products of a new anti-cancer agent, Pt(IV)(cyclohexyldiamine)Cl4, with guanosine and 9-methylguanine: first crystal structures of Pt(cyclohexyldiamine) complexes with a nucleobase and a nucleoside.

  1988cited by this paper
• Preclinical studies identifying carboplatin as a viable cisplatin alternative.

  1985cited by this paper
• Does the Antitumoral Activity of Platinum(IV) Derivatives Result from their in Vivo Reduction?

  1983cited by this paper
• Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations

  1978cited by this paper

• New Developments and Approaches in the Platinum Arena

  2012cites this paper
• The development of platinum compounds and their possible combination.

  2006cites this paper
• Oxaliplatin-related neurotoxicity: how and why?

  2006cites this paper
• Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812)

  2004cites this paper
• Studies on Tumour Active Compounds with Multiple Metal Centres

  2003cites this paper
• Sample preparation for metal-based drugs

  2003cites this paper